The European Health Stakeholder Group urged the European Commission to formalise the United Kingdom’s association to Horizon Europe without further delay.
In a statement published on 8 December, the European Health Stakeholder Group, of which FEAM is a member, stressed that the COVID-19 pandemic has highlighted the critical value of global partnerships to advance scientific discovery and innovation. The group has also underlined the importance of international collaborations resulting from the relationships with the UK.
“We have all reaped the mutual health benefits of these collaborations. Together, we have significantly advanced health care across Europe, saving and improving citizens’ lives. Clinical trials, particularly on diseases with limited patient populations, have been heavily reliant on EU-UK collaboration, while close research and innovation partnerships continue to accelerate life-changing medical research,” the statement says.
In the document, the group also pointed that, at this moment, many profound and long-lasting EU-UK research partnerships are at stake. “These are of high value to Europe as a whole – and to the world at large. We owe it to future generations in the EU and beyond to ensure that the new EU-UK relationship best serves them through research.”
The European Health Stakeholder Group concludes the statement by urging the European Commission to formalise the United Kingdom’s association to Horizon Europe without further delay.
